Labomar announces that it has acquired, by exercising the option right, 7% of the capital of Welcare Research held by Think FWD, a company that has been operating in strategic consulting and investment activities since 2013. The current acquisition joins the one previously made in July, involving 63% of the share capital of Welcare Research, and therefore brings Labomar’s overall stake in the Orvieto-based company, specialized in the production of dedicated medical devices, to 70%. to skin care. The payment of the price paid to Think FWD was made using Labomar’s own resources, therefore without resorting to the banking system.
Welcare Research and its subsidiary Welcare Industries entered the consolidation perimeter of the Labomar Group starting from the second half of 2021 and will contribute to its growth strategy, also from an internationalization point of view, thanks to the strong interconnections that their respective products and the absence of any overlaps in terms of the market and customers.